Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
Date:2/26/2009

SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the fourth quarter and year-ended December 31, 2008.

"2008 was a very productive year at Anadys," said Steve Worland, Ph.D., Anadys' President and CEO. "We resumed clinical development activities and positioned our HCV programs for viral load data, which we now have begun to see. We have established ANA598 as a potent antiviral, demonstrating in three days a greater viral load decline as a single agent than has been reported for any other non-nucleoside polymerase inhibitor. And today we are reporting that we have seen preliminary indications of antiviral activity with ANA773, our oral inducer of endogenous interferons that acts via the TLR7 pathway. We believe that ANA598, and potentially ANA773, hold promise to become important parts of future combination regimens to treat HCV patients."

Financial Results

As of December 31, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $27.9 million.

During the fourth quarter of 2008 the Company had no revenue, compared to $0.2 million for the same quarter of 2007. The revenue in the fourth quarter of 2007 was primarily derived from the successful completion of our screening collaboration with Aphoenix, Inc.

Research and development expenses were $6.9 million for the fourth quarter of 2008 and 2007. During the fourth quarter of 2008, cost savings derived from Anadys' completed strategic restructuring were offset by significant increases in development costs for ANA598 and ANA773.

Gener
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
4. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Within3 Expands into Mobile Applications 2RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2The American Medical Money Machine the Destruction of Healthcare in America and the Rise of Medical Tourism a New Book by James R Goldberg 60129 1The American Medical Money Machine the Destruction of Healthcare in America and the Rise of Medical Tourism a New Book by James R Goldberg 60129 2The American Medical Money Machine the Destruction of Healthcare in America and the Rise of Medical Tourism a New Book by James R Goldberg 60129 3The American Medical Money Machine the Destruction of Healthcare in America and the Rise of Medical Tourism a New Book by James R Goldberg 60129 4The American Medical Money Machine the Destruction of Healthcare in America and the Rise of Medical Tourism a New Book by James R Goldberg 60129 5Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy According to HealthCore Study Presented at 5722 1Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy According to HealthCore Study Presented at 5722 2Medical Food Reduces Medical Costs and Use of Anticonvulsant Medication When Treating Diabetic Neuropathy According to HealthCore Study Presented at 5722 3UT Southwestern patient first in North Texas to receive newest generation heart failure device 10532 1UT Southwestern patient first in North Texas to receive newest generation heart failure device 10532 2UT Southwestern patient first in North Texas to receive newest generation heart failure device 10532 3
Other Medicine Technology:DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education 2DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education 3Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 2Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 3Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 4Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 5Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease 6